Metabolic hormones regulate insulin-like growth factor binding protein-1 mRNA levels in primary cultured salmon hepatocytes; lack of inhibition by insulin

A L Pierce1,2, M Shimizu1,2, L Felli1,2, P Swanson1,2 and W W Dickhoff1,2

1Integrative Fish Biology Program, Northwest Fisheries Science Center, National Marine Fisheries Service, 2725 Montlake Boulevard E., Seattle, Washington 98112, USA
2School of Aquatic and Fishery Sciences, University of Washington, Seattle, Washington 98195, USA

Abstract

IGF-binding proteins (IGFBPs) modulate the effects of the IGFs, major stimulators of vertebrate growth and development. In mammals, IGFBP-1 inhibits the actions of IGF-I. Rapid increases in circulating IGFBP-1 occur during catabolic states. Insulin and glucocorticoids are the primary regulators of circulating IGFBP-1 in mammals. Insulin inhibits and glucocorticoids stimulate hepatocyte IGFBP-1 gene expression and production. A 22 kDa IGFBP in salmon blood also increases during catabolic states and has recently been identified as an IGFBP-1 homolog. We examined the hormonal regulation of salmon IGFBP-1 mRNA levels and protein secretion in primary cultured salmon hepatocytes. The glucocorticoid agonist dexamethasone progressively increased hepatocyte IGFBP-1 mRNA levels (eightfold) and medium IGFBP-1 immunoreactivity over concentrations comparable with stressed circulating cortisol levels ($10^{-5}$–$10^{-6}$ M). GH progressively reduced IGFBP-1 mRNA levels (0.3–fold) and medium IGFBP-1 immunoreactivity over physiological concentrations ($5\times10^{-11}$–$5\times10^{-9}$ M). Unexpectedly, insulin slightly increased hepatocyte IGFBP-1 mRNA (1.4–fold) and did not change medium IGFBP-1 immunoreactivity over physiological concentrations and above ($10^{-2}$–$10^{-6}$ M). Triiodothyronine had no effect on hepatocyte IGFBP-1 mRNA, whereas glucagon increased IGFBP-1 mRNA (2.2–fold) at supraphysiological concentrations ($10^{-6}$ M). This study suggests that the major inhibitory role of insulin in the regulation of liver IGFBP-1 production in mammals is not found in salmon. However, regulation of salmon liver IGFBP-1 production by other metabolic hormones is similar to what is found in mammals.


Introduction

The mitogenic insulin-like growth factors (IGF-I and IGF-II) circulate bound to members of a family of IGF-binding proteins (IGFBPs). In mammals, six IGFBPs have been identified, which can both enhance and inhibit the actions of the IGFs (Duan 2002, Firth & Baxter 2002, Frystyk 2004). Out of the IGFBPs studied to date, IGFBP-1 is unique in that it responds rapidly and strongly to metabolic status and stress (Lee et al. 1993, 1997). Plasma levels routinely fluctuate more than tenfold daily, increasing rapidly during fasting, stress, and in other catabolic states, and decreasing after meals. IGFBP-1 inhibits the actions of IGF-I in vitro and in vivo by decreasing levels of free IGF-I available to bind the IGF-I receptor. Plasma IGFBP-1 levels are determined by liver production of the protein, which has a short half life in the circulation.

In postnatal mammals, plasma IGFBP-1 levels are regulated in accordance with metabolic status through effects of metabolic hormones on hepatocyte IGFBP-1 gene transcription. Insulin plays a primary role by strongly inhibiting IGFBP-1 production (Unterman et al. 1991, Lee et al. 1993, 1997, Frystyk 2004). Negative regulation of hepatocyte IGFBP-1 production by insulin accounts for the postprandial decrease in plasma IGFBP-1 levels, the effects of diet composition on plasma IGFBP-1 levels, and the inverse correlation between circulating insulin and IGFBP-1 levels. Glucocorticoids stimulate hepatocyte IGFBP-1 gene transcription and increase circulating IGFBP-1 levels; however, suppression of IGFBP-1 production by insulin dominates stimulation by glucocorticoids (Unterman et al. 1991). The effects of insulin and cortisol on IGFBP-1 gene transcription are mediated by contiguous negative and positive insulin and glucocorticoid-response elements in mammalian IGFBP-1 promoters respectively (Goswami et al. 1994, Suwanichkul et al. 1994). While insulin and glucocorticoids are thought to be the primary hormonal regulators of liver IGFBP-1 production, other anabolic and catabolic hormones also play roles. In general, growth hormone (GH) decreases and glucagon increases hepatocyte IGFBP-1 mRNA levels (Denver & Nicoll 1994, Kachra et al. 1994, Thissen et al. [2002–0795/06/0191–379] © 2006 Society for Endocrinology Printed in Great Britain DOI: 10.1677/joe.1.06986 Online version via http://www.endocrinology-journals.org

Downloaded from Bioscientifica.com at 06/07/2022 11:03:34AM via free access
Cytokines directly induce IGFBP-1 (Lee et al. 1997). Possibly indirect induction by thyroid hormones and catecholamines have been reported (Lee et al. 1997). In addition to hormonal regulation, primary hepatocyte IGFBP-1 mRNA levels are directly increased by low amino acid levels (Thissen et al. 1994) and by hypoxia (Popovici et al. 2001, Scharf et al. 2005). Both the regulation of IGFBP-1 by metabolic status and stress and its function as an inhibitor of IGF actions appear to be conserved between teleost fishes and other vertebrates (Kelley et al. 2001, 2002, Shimizu et al. 2005, 2006, Wood et al. 2005). IGFBPs are found in western ligand blots of fish plasma. Lower molecular weight (20–30 kDa) IGFBPs are increased in catabolic states in a number of fish species, suggesting that one of these bands may correspond to IGFBP-1 (Siharath et al. 1996, Park et al. 2000, Kelley et al. 2001, Kajimura et al. 2003). However, until recently, definitive identification of these proteins has been lacking due to the absence of molecular sequence data. Recent studies have shown that liver IGFBP-1 gene transcription is induced by hypoxia in adult gobies (Gillichthyes mirabilis) and zebrafish (Danio rerio) (Gracey et al. 2001, Maures & Duan 2002), that the induction of IGFBP-1 partially underlies hypoxia-induced growth retardation in zebrafish embryos (Kajimura et al. 2005) and that the zebrafish IGFBP-1 promoter contains a functional hypoxia-response element (Kajimura et al. 2006).

These findings suggest that both the growth-inhibitory role and the regulation of IGFBP-1 may be highly conserved among vertebrates. Nucleotide sequence data reveal that a 22 kDa IGFBP in Chinoook salmon (Oncorhynchus tshawytscha) plasma is an IGFBP-1 homolog (Shimizu et al. 2005). Salmon IGFBP-1 is most highly expressed in the liver, suggesting a hepatic source for circulating IGFBP-1. In order to elucidate endocrine mechanisms in the metabolic regulation of liver IGFBP-1 production in salmon, we examined the effects of metabolic hormones on IGFBP-1 mRNA levels and protein secretion in primary cultured coho salmon (Oncorhynchus kisutch) hepatocytes.

Materials and Methods

Animals

Coho salmon (O. kisutch) were raised in 1.3 m diameter cylindrical tanks with recirculated fresh water at 11–12 °C under simulated natural photoperiod at the Northwest Fisheries Science Center (Seattle, WA, USA). Fish were fed BioOregon-grower pellets at a ration of 0.6% body weight per day. For cultures, 2-year-old fish were used and fasted for 1 day prior to hepatocyte isolation to reduce potential contamination of cultures from gut contents. Data shown are from the following cultures: 10/12/02, independent cultures from three immature female fish, 143, 149, and 157 g for Fig. 1A and B; 12/7/02 pooled cells from two immature male fish, 146 and 179 g for Fig. 3 and one replicate culture in Fig. 1B and C; 6/12/04 pooled cells from two immature male fish, 262 and 275 g for Figs 2 and 4A and B; 8/13/05 independent cultures from one immature male fish 349 g and one immature female fish 292 g for Fig. 1C. Experiments complied with the guidelines of the University of Washington Institutional Animal Care and Use Committee.

Hepatocyte culture, RNA isolation, and cDNA synthesis

Hepatocytes were isolated and cultured as previously described (Pierce et al. 2004). Cells were cultured on Falcon Primaria 24-well plates at 15 °C in modified RPMI 1640 medium (Gibco BRL, Gaithersburg, MD, USA; buffer changed to 20 mM HEPES, 5 mM NaHCO₃). Hepatocytes were plated at a density of approximately 4×10⁶ cells/well in the plain medium and allowed to adhere for 24 h, and then medium was changed to test medium containing hormones. Cultures were stopped 18 h later by adding Tri-Reagent (Molecular Research Center, Cincinnati, OH, USA) to wells. RNA was isolated following the MRC protocol with bromochloro-propane as the phase separation reagent and two 75% ethanol washes. RNA was quantitated by spectrophotometry (260:280 ratios 1.8–2.0), and diluted to 10 ng/µl. First-strand cDNA was synthesized in 15 µl reverse transcription (RT) reactions with 3 µl RNA template, 2.5 U/µl SuperScript II reverse transcriptase (Invitrogen), 5 µM random hexamer primers, 500 µM dNTPs, 0.4 U/µl RNase inhibitor (Applied Biosystems, Inc. (ABI), Foster City, CA, USA), 10 mM DTT, and 1× RT buffer, incubated at 25 °C for 10 min, 48 °C for 60 min, and 95 °C for 5 min.

Hormones

Native coho salmon GH was purified by HPLC (Rand-Weaver & Kawachi 1992). Native coho salmon insulin was a generous gift from Dr Erika Plisetskaya (University of Washington, Seattle). Triiodothyronine (T₃), water-soluble dexamethasone (2-hydroxypropyl-β-cyclodextrin encapsulated), native bovine insulin, and native bovine glucagon were purchased from Sigma.

Real-time quantitative RT-PCR (qPCR) and radioimmunoassays

Hepatocyte IGFBP-1 mRNA levels were quantified using a TaqMan probe qPCR assay with the amplicon in the region of the transcript covering the predicted exon 2/exon 3 junction (Table 1). PCR efficiency was reasonable (slope = −3.642; Table 1) and equal between input cDNA template from Chinoook and coho salmon liver and coho salmon primary cultured hepatocytes. No amplification was observed in wells containing no template, coho salmon genomic DNA, or experimental hepatocyte culture and liver cDNA preparations in which the RT enzyme was omitted from the RT reaction. No bias across the PCR plate was found when
Salmon growth hormone receptor (GHR) mRNA levels were quantified using a TaqMan probe qPCR assay in the extracellular domain as previously described (Fukada et al. 2004). mRNA level data were normalized to the mRNA level of acidic ribosomal phosphoprotein P0 (ARP), using an efficiency corrected relative expression technique (Pierce et al. 2004). To minimize the effects of variability in RNA quantification, RNA quality, and RT efficiency, RNA from each cell culture well was reverse transcribed once and the qPCR assays for IGFBP-1, ARP, and GHR (where measured) run from the same cDNA preparation. A single replicate of each PCR was run. Assays were run in 96-well format on an ABI 7700 qPCR machine. All samples to be compared were run on the same PCR plate. As a standard, a fivefold serial dilution from a coho salmon liver (highest concentration 100 ng/ml RNA input to RT reaction, four standards, three replicate wells per standard) was run on each plate.

Medium IGFBP-1 protein levels were measured with a newly developed RIA (Shimizu et al. 2006). Some nonparallelism was observed in serial dilutions of hepatocyte-conditioned medium versus assay standards and serial dilutions of recombinant IGFBP-1.

Table 1 Primer and probe sequences for salmon IGFBP-1 TaqMan RT-PCR assay

<table>
<thead>
<tr>
<th>Element</th>
<th>Sequence (5'→3')</th>
<th>Amplicon; PCR efficiency</th>
</tr>
</thead>
<tbody>
<tr>
<td>F primer</td>
<td>AACACCATCCGCAAGAAACTG</td>
<td>68 bp</td>
</tr>
<tr>
<td>R primer</td>
<td>TTGTGAGAGCCCTACGCA</td>
<td>0.879 ± 0.007</td>
</tr>
<tr>
<td>Probe</td>
<td>Fam-TGGAACAGGGGTTCCTGCA-CACATTG-Tamra</td>
<td></td>
</tr>
</tbody>
</table>

F, forward; R, reverse.
dilution of Chinook salmon serum (data not shown). Therefore, measurements of IGFBP-1 protein levels in hepatocyte culture medium are designated as immunoreactivity and should only be used for relative comparisons.

Data analysis

mRNA levels were expressed relative to the control treatment for each fish or hepatocyte pool. In the factorial experiments (Fig. 1), as the pattern of responses between different cultures was always similar, but the magnitude of responses sometimes differed, the data from each culture was normalized to the average response level of all cultures. Treatment and fish effects were examined by one- or two-way ANOVA followed by the Bonferroni–Dunn test. Results were considered statistically significant at $P<0.05$.

Results

Dexamethasone ($10^{-6}$ M) strongly increased IGFBP-1 mRNA levels in salmon hepatocytes (Fig. 1A). The increase in IGFBP-1 mRNA levels was substantial (12-1-, 7.9-, and 5.7-fold). After normalization to the average dexamethasone response level, there were no significant differences between cultures ($n=3$). GH ($5 \times 10^{-9}$ M) significantly reduced dexamethasone-stimulated IGFBP-1 mRNA levels. GH tended to reduce basal IGFBP-1 mRNA levels; however, the reduction was not significant ($P=0.112$). Triiodothyronine ($10^{-7}$ M) did not significantly affect IGFBP-1 mRNA levels alone or in combination with GH.

A marginally nonsignificant increase in IGFBP-1 mRNA levels occurred with insulin treatment ($P=0.054$; Fig. 1B). Suppression of IGFBP-1 mRNA levels by insulin was not found in four independent cultures, using both bovine insulin (three cultures) and salmon insulin (one culture). GH significantly decreased IGFBP-1 mRNA levels in these cultures (to 0.30-, 0.35-, 0.57-, and 0.67-fold control levels). After normalization to the average GH response level, there were no significant differences between cultures. Insulin significantly attenuated the GH suppression of IGFBP-1 mRNA levels, but did not restore IGFBP-1 mRNA to control levels.

Glucagon ($10^{-6}$ M) increased IGFBP-1 mRNA levels (Fig. 1C). The increase in IGFBP-1 mRNA levels with glucagon was less than with dexamethasone (2.4-, 3.6-, and 3.8-fold in three independent cultures). GH significantly reduced glucagon-stimulated IGFBP-1 mRNA levels. Once again, a nonsignificant reduction in basal IGFBP-1 mRNA levels was consistently found with GH ($P=0.0552$).

Dexamethasone increased IGFBP-1 mRNA levels in a concentration-dependent manner (Fig. 2A). The increase over control levels became significant at $10^{-5}$ M and reached maximal levels of 8.1-fold control levels at $10^{-7}$ M. Medium IGFBP-1 immunoreactivity levels increased with increasing dexamethasone concentration in a similar concentration-dependent manner, becoming elevated versus controls at $10^{-9}$ M and maximal at $10^{-6}$ M. A strong positive correlation was found between cellular IGFBP-1 mRNA levels and medium IGFBP-1 protein immunoreactivity in the dexamethasone concentration-response study ($r^2=0.710$).

GH ($5 \times 10^{-9}$ M) consistently reduced both basal and hormone-stimulated IGFBP-1 mRNA levels in survey experiments, although this effect was not always statistically significant. To examine regulation by GH more closely, a concentration-response study was conducted. GH reduced IGFBP-1 mRNA levels in a concentration–dependent manner (Fig. 3). The decrease versus control levels became significant at $2.5 \times 10^{-10}$ M GH and attained a maximum reduction of 0.82-fold control levels at $5 \times 10^{-7}$ M GH. Medium IGFBP-1 immunoreactivity levels decreased with increasing GH concentrations from $5 \times 10^{-11}$ to $2.5 \times 10^{-9}$ M. A positive correlation was found between cellular IGFBP-1 mRNA level and medium IGFBP-1 protein immunoreactivity in the GH concentration-response study ($r^2=0.456$).

The lack of inhibition of IGFBP-1 mRNA levels by insulin was confirmed in a concentration–response study using salmon insulin (Fig. 4A). Insulin significantly increased IGFBP-1 mRNA levels at $10^{-8}$ and $10^{-7}$ M; maximum induction was 1.38-fold control levels. No significant effect of insulin treatment on medium IGFBP-1 immunoreactivity was found (ANOVA, $P=0.2821$). No significant correlation was found between cellular IGFBP-1 mRNA level and medium IGFBP-1 protein immunoreactivity in the insulin concentration–response study. As expected, insulin significantly reduced mRNA levels of the salmon GHR in these cells (Pierce et al. 2005a), showing that cells were able to respond to insulin (Fig. 4B).

A concentration-response study with glucagon found a significant induction (2.17-fold controls) only at $10^{-6}$ M glucagon (Fig. 5). Lower glucagon concentrations did not significantly affect IGFBP-1 gene mRNA levels.

The $C_T$ for ARP did not vary between treatments in any experiment, indicating that treatments did not affect our reference gene.

Discussion

The glucocorticoid receptor agonist dexamethasone strongly increased IGFBP-1 mRNA levels in cultured salmon hepatocytes and increased IGFBP-1 immunoreactivity in conditioned medium. This result is consistent with previous studies in fish. Only a few previous fish studies have positively identified IGFBP-1. In zebrafish, fasting strongly increased liver IGFBP-1 mRNA levels (Maures & Duan 2002). In Chinook salmon, fasting and seawater transfer caused increases in plasma levels of a 22 kDa IGFBP on western ligand blots; this band was positively identified as salmon IGFBP-1 (Shimizu et al. 2005). Cortisol would be expected to increase during fasting and seawater transfer. A larger number of studies have used western ligand blotting without
positive identification of IGFBP bands. In tilapia, cortisol injection increased plasma levels of 22 and 28 kDa IGFBPs (Kajimura et al. 2003). In channel catfish, dietary cortisol supplementation increased plasma levels of a 20 kDa IGFBP (Peterson & Small 2005). In gobies, fasting and experimentally induced diabetes caused increases in plasma levels of cortisol and 24 and 30 kDa IGFBPs, whereas in jack mackerel, stress caused increases in plasma levels of cortisol and 24 and 30 kDa IGFBPs (Kelley et al. 2001). In striped bass, fasting strongly increased plasma levels of a 25 kDa IGFBP (Siharath et al. 1996). The results of the present study support the proposal that the increase in IGFBP-1 found in these stressful physiological states is mediated by cortisol stimulation of liver IGFBP-1 production and that this regulation is highly conserved among fishes (Kelley et al. 2001). Further, our results suggest that at least one of the lower molecular weight IGFBPs on ligand blots is IGFBP-1.

Glucocorticoids directly increase hepatocyte IGFBP-1 production and increase circulating IGFBP-1 levels in mammals (Unterman et al. 1991, Lee et al. 1997). The glucocorticoid effect on IGFBP-1 is mediated by a glucocorticoid response element in the promoter of mammalian IGFBP-1 genes (Goswami et al. 1994, Suwannichkul et al. 1994). It is not known if fish IGFBP-1 promoters contain such an element. In mammals, IGFBP-1 inhibits IGF actions and reduces growth (Firth & Baxter 2002, Frystyk 2004). Stress and cortisol treatments reduce growth in fishes (Barton & Iwama 1991, Peterson & Small 2005). Recent studies in zebrafish show that elevations in IGFBP-1 mRNA levels cause growth retardation during zebrafish development (Kajimura et al. 2005). Thus, the induction of IGFBP-1 by cortisol is likely to be part of the mechanism by which stress inhibits growth in salmon and other fishes. Hypoxia increases hepatic IGFBP-1 mRNA levels in adult gobies and zebrafish (Gracey et al. 2001, Maures & Duan 2002). This effect might be mediated by cortisol. However, in mammalian hepatocyte culture, hypoxia directly increases hepatocyte IGFBP-1 mRNA levels (Popovici et al. 2001, Scharf et al. 2005). Further, the zebrafish IGFBP-1 promoter contains a functional hypoxia-response element, indicating that cellular pathways for direct hypoxia induction of IGFBP-1 exist in fishes (Kajimura et al. 2006). A 21 kDa IGFBP increased during gradual seawater adaptation in rainbow trout; however, cortisol increased only slightly and transiently (Shepherd et al. 2005). Further studies are required to evaluate the role of cortisol in the regulation of fish IGFBP-1 by various physiological stressors.

Dexamethasone concentrations of $10^{-12}$–$10^{-10}$ M did not change IGFBP-1 mRNA or medium protein levels. The full range of regulation occurred from $10^{-10}$ to $10^{-8}$ M, similar to the range of cortisol from basal to stressed levels respectively (Barton & Iwama 1991). However, in a previous study using the same culture conditions and hormones, dexamethasone substantially reduced GH-stimulated IGF-I mRNA levels at $10^{-12}$ M, and maximal inhibition of the IGF-I response to GH occurred at $10^{-8}$ M dexamethasone and above (Pierce et al. 2005a). Recently, two functional glucocorticoid receptors with different sensitivities of transactivation activity in response to cortisol and dexamethasone were characterized in rainbow trout (Bury et al. 2003). The differing
concentration-response curves for the IGF-I and IGFBP-1 response to dexamethasone are consistent with the possibility that different glucocorticoid receptors may mediate these effects. Alternatively, the difference in sensitivity may occur downstream from the receptor.

GH inhibited IGFBP-1 mRNA levels to approximately one-third of control levels in cultured salmon hepatocytes. Inhibition of IGFBP-1 mRNA levels by GH occurred at 0.25 nM (5.5 ng/ml) and above, comparable with circulating concentrations during GH secretion episodes (e.g. Pierce et al. 2005b). GH (2.5 nM) also decreased conditioned medium IGFBP-1 immunoreactivity. GH significantly attenuated dexamethasone-stimulated IGFBP-1 mRNA levels, but did not reduce it to control levels, indicating that neither effect is completely dominant over the other. Negative regulation of a 20 kDa IGFBP by GH has been described in tilapia; this band was strongly increased by hypophysectomy and reduced by GH replacement (Park et al. 2000). Based on regulation by GH, this band functionally corresponds to tilapia IGFBP-1. While initially controversial, it is now clear that GH reduces hepatocyte IGFBP-1 mRNA levels and protein secretion in mammals (Norrelund et al. 1999). However, inhibition of IGFBP-1 by GH is not thought to be of great physiological importance in mammals, because inhibition by insulin is much stronger (Lee et al. 1997). Based on the limited comparative data now available, inhibition of liver IGFBP-1 production by GH appears highly conserved among vertebrates. The lack of an insulin effect in coho salmon suggests that inhibition of IGFBP-1 by GH may be of greater physiological significance in this species. Inhibition of IGFBP-1 by GH is consistent with the growth stimulatory role of GH. Further, in mammals, IGFBP-1 may reduce negative feedback from free IGF-I on GH secretion, linking GH and IGFBP-1 in a negative feedback loop (Frystyk 2004). Negative feedback from IGF-I on GH secretion has also been demonstrated in fish (Perez-Sanchez et al. 1992).

Insulin did not change or slightly increased IGFBP-1 mRNA levels in cultured salmon hepatocytes. This result was unexpected; in mammals, insulin strongly represses liver IGFBP-1 mRNA levels in vivo and in vitro. The lack of repression of IGFBP-1 mRNA levels by insulin cannot be attributed to an anomalous culture, since it was found in five independent cell preparations, or to unresponsive cells, since insulin was effective at reducing GHR mRNA levels and inhibiting the IGF-I response to GH in these cultures (Fig. 4, Pierce et al. 2005a). Bovine and salmon insulin had similar effects, suggesting that the lack of repression of IGFBP-1 by insulin was not due to the use of heterologous insulin. The lack of repression by insulin was confirmed at the protein level; insulin did not significantly repress conditioned medium IGFBP-1 immunoreactivity levels. Cultured salmon hepatocytes responded as expected in terms of IGFBP-1 response to dexamethasone, GH, and glucagon. Therefore, we believe that the most reasonable interpretation of our results is that the role of insulin in the regulation of hepatocyte IGFBP-1 mRNA levels differs between salmon and mammals. In vivo, insulin increased rapidly and strongly after

Figure 4 (A) Effect of medium insulin concentration on IGFBP-1 mRNA levels (points), and conditioned medium IGFBP-1 protein immunoreactivity (bars) in primary cultured salmon hepatocytes. (B) Effect of medium insulin concentration on growth hormone receptor (GHR) mRNA levels in primary cultured salmon hepatocytes. In both panels: error bars show standard error; n = 4–5 wells per point or bar; points or bars not sharing a superscript letter differ significantly (P<0.05, Bonferroni–Dunn test).

Figure 5 Effect of medium glucagon concentration on IGFBP-1 mRNA levels in primary cultured salmon hepatocytes. Error bars show standard error; n = 4–5 wells per point; points not sharing a superscript letter differ significantly (P<0.05, Bonferroni–Dunn test).
a meal in coho salmon, whereas IGFBP-1 decreased slowly and moderately (M Shimizu, unpublished observations). In the goby, removal of the endocrine pancreas resulted in the absence of insulin, and caused increases in plasma levels of glucose, cortisol, and a 24 kDa IGFBP (putative goby IGFBP-1), all of which were normalized by insulin injection (Kelley et al. 2001). Thus, the increase in putative goby IGFBP-1 can be explained by regulation by cortisol only. However, direct regulation of hepatocyte IGFBP-1 production by insulin must be examined in more fish species before any conclusions can be drawn about how widespread the lack of insulin regulation of IGFBP-1 may be. Further, it must be noted that the results in mammals are based on studies in humans and laboratory rodents. In other mammalian species, ligand blotting studies have found that lower-molecular weight IGFBPs (putative IGFBP-1s) sometimes did not increase as expected during catabolic states (Maxwell et al. 1998, Schmidt & Kelley 2001).

Insulin attenuated the repression of IGFBP-1 by GH, and slightly increased basal IGFBP-1 mRNA levels at intermediate concentrations. The magnitude of these effects was much less than those of dexamethasone and GH. The effect on GH-stimulated IGFBP-1 mRNA levels may be due to insulin induction of GH resistance. Insulin reduced mRNA levels of the GH receptor and reduced the stimulatory effect of GH on IGF-1 mRNA levels in salmon hepatocytes (Pierce et al. 2005a, Fig. 4). The slight stimulation of basal IGFBP-1 may be due to insulin influence on hepatocyte metabolism. In fish hepatocytes, insulin stimulates uptake of amino acids and glucose and modulates many aspects of metabolic substrate metabolism (Mommsen & Plisetskaya 1991, Moon 2004).

The correlation between cellular mRNA levels and conditioned medium IGFBP-1 immunoreactivity was strong in the dexamethasone concentration-response study (r² = 0.710), intermediate in the GH concentration-response study (r² = 0.456), and not significant in the insulin concentration-response study. This was probably due to decreasing range of variability of input data. The strong correlation when a large range of input variability was provided is consistent with regulation of salmon liver IGFBP-1 production at the level of gene transcription, as in mammals (Lee et al. 1993, 1997).

Glucagon increased IGFBP-1 mRNA levels in salmon hepatocytes, but only at 10⁻⁶ M, a concentration the liver would not likely experience physiologically. Glucagon increased IGFBP-1 mRNA levels and protein secretion at concentrations approximately 100-fold lower in primary rat hepatocytes (Denver & Nicoll 1994, Kachra et al. 1994), and the responses to dexamethasone and GH occurred at physiological concentrations in the present study. Therefore, the present study suggests that glucagon may not regulate salmon liver IGFBP-1 production under normal physiological conditions. The effect found at 10⁻⁶ M may be mediated by an effect on hepatocyte metabolism (Moon 2004). Triiodothyronine (10⁻⁷ M) did not significantly change IGFBP-1 mRNA levels in salmon hepatocytes. Triiodothyronine increases IGFBP-1 mRNA levels in mammalian hepatoma cell lines, but may decrease it in mammalian primary hepatocytes (Kachra et al. 1994, Demori et al. 1997). These and other divergent results on IGFBP-1 regulation in mammalian cell culture may be due to differences in culture conditions. Salmon primary hepatocytes do not require medium serum or hormonal supplements to maintain cell viability.

Our studies on the regulation of GH/IGF axis components in primary salmon hepatocytes show that the role of insulin in the regulation of the GH/IGF axis in salmon is quite different from the mammalian model. In salmon hepatocytes, insulin induced GH resistance in terms of IGF-1 mRNA levels (Pierce et al. 2005a), and did not reduce IGFBP-1 mRNA levels (present study). In mammals, insulin enhances GH sensitivity in terms of IGF-I gene expression, and strongly inhibits IGFBP-1 gene expression. The significance of these differences is not yet clear. The strong linkage between insulin and IGFBP-1 in mammals has led to the proposal that IGFBP-1 may play a role in glucose counter-regulation by inhibiting the metabolic effects of IGFs (Lee et al. 1997, Frystyk 2004). In fishes, glycemic control is much less stringent than in mammals (Mommsen & Plisetskaya 1991, Kelley et al. 2001, Moon 2001). The lack of a linkage between insulin and IGFBP-1 in coho salmon is consistent with the lesser importance of glycemic control in this species. The negative regulation of IGF-I by insulin is consistent with a greater role for insulin in growth (Mommsen and Plisetskaya 1991).

Acknowledgements

We thank Dr Erika Plisetskaya for the generous gift of salmon insulin, and Dr Brian Beckman for hatchery management.

Funding

This project was supported by National Research Initiative Competitive Grant no. 2003-35206-13631 from the USDA Cooperative State Research, Education, and Extension Service. Support was also provided by fellowships from the University of Washington School of Aquatic and Fishery Sciences, and grants from the Bonneville Power Administration (projects 92-022 and 93-056). The authors declare that there is no conflict of interest that would prejudice the impartiality of this scientific work. This publication was partially funded by the Joint Institute for the Study of the Atmosphere and Ocean (JISAO) under NOAA Cooperative Agreement no. NA17RJ1232, Contribution no. 1319.

References


Received 31 May 2006
Received in final form 7 July 2006
Accepted 26 July 2006